Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine

Co-Administration of GSK Biologicals' Meningococcal Vaccine GSK134612 With Infanrix Hexa™, Compared to Individual Administration of Each Vaccine, in Healthy 12- Through 23-Month-Old Children

The purpose of this study is to demonstrate, in 12-23 months old subjects, the non-inferiority of meningococcal vaccine GSK134612 co-administered with Infanrix hexa™, compared to each vaccine administered individually and to licensed meningococcal vaccine Meningitec™.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Study Overview

• Status: Completed
• Conditions: Infections, Meningococcal
• Intervention / Treatment: Biological: Meningococcal vaccine GSK134612; Biological: Infanrix™ hexa; Biological: Meningitec™

Detailed Description

Multicentre study with 4 parallel groups. One group will receive GSK134612 co-administered with Infanrix hexa™, two groups will receive sequential administration of GSK134612 and Infanrix hexa™ and the final group will receive Meningitec™.

For subjects in Groups B and C, three blood samples will be taken: prior to first vaccination and 1 month after each vaccination.

For subjects in Groups A and D, two blood samples will be taken: prior to and 1 month after vaccination.

• Study Type: Interventional
• Enrollment (Actual): 793
• Phase: Phase 3

Contacts and Locations

Study Locations

• Austria
  • Eferding, Austria, A-4070
    • GSK Investigational Site
  • Neufeld/Leitha, Austria, A 2491
    • GSK Investigational Site
  • Salzburg, Austria, A-5020
    • GSK Investigational Site
  • Villach, Austria, A-9500
    • GSK Investigational Site
  • Wels, Austria, A-4600
    • GSK Investigational Site
• Germany
  • Berlin, Germany, 10315
    • GSK Investigational Site
  • Berlin, Germany, 13055
    • GSK Investigational Site
  • Berlin, Germany, 12627
    • GSK Investigational Site
  • Berlin, Germany, 12679
    • GSK Investigational Site
  • Berlin, Germany, 13507
    • GSK Investigational Site
  • Berlin, Germany, 14197
    • GSK Investigational Site
  • Berlin, Germany, 13355
    • GSK Investigational Site
  • Berlin, Germany, 10627
    • GSK Investigational Site
  • Hamburg, Germany, 22307
    • GSK Investigational Site
  • Hamburg, Germany, 22089
    • GSK Investigational Site
  • Baden-Wuerttemberg
    • Boennigheim, Baden-Wuerttemberg, Germany, 74357
      • GSK Investigational Site
    • Bretten, Baden-Wuerttemberg, Germany, 75015
      • GSK Investigational Site
    • Heilbronn, Baden-Wuerttemberg, Germany, 74072
      • GSK Investigational Site
    • Karlsruhe, Baden-Wuerttemberg, Germany, 76189
      • GSK Investigational Site
    • Mannheim, Baden-Wuerttemberg, Germany, 68167
      • GSK Investigational Site
    • Marbach, Baden-Wuerttemberg, Germany, 71672
      • GSK Investigational Site
    • Oberkirch, Baden-Wuerttemberg, Germany, 77704
      • GSK Investigational Site
    • Oberstenfeld, Baden-Wuerttemberg, Germany, 71720
      • GSK Investigational Site
    • Pforzheim, Baden-Wuerttemberg, Germany, 75172
      • GSK Investigational Site
    • Schwaebisch-Hall, Baden-Wuerttemberg, Germany, 74523
      • GSK Investigational Site
    • Stuttgart, Baden-Wuerttemberg, Germany, 70469
      • GSK Investigational Site
    • Tettnang, Baden-Wuerttemberg, Germany, 88069
      • GSK Investigational Site
  • Bayern
    • Aschaffenburg, Bayern, Germany, 63739
      • GSK Investigational Site
    • Kaufbeuren, Bayern, Germany, 87600
      • GSK Investigational Site
    • Kaufering, Bayern, Germany, 86916
      • GSK Investigational Site
    • Kronach, Bayern, Germany, 96317
      • GSK Investigational Site
    • Muenchen, Bayern, Germany, 81735
      • GSK Investigational Site
    • Muenchen, Bayern, Germany, 81675
      • GSK Investigational Site
    • Muenchen, Bayern, Germany, 81241
      • GSK Investigational Site
    • Noerdlingen, Bayern, Germany, 86720
      • GSK Investigational Site
    • Olching, Bayern, Germany, 82140
      • GSK Investigational Site
  • Hessen
    • Braunatal, Hessen, Germany, 34225
      • GSK Investigational Site
    • Eschwege, Hessen, Germany, 37269
      • GSK Investigational Site
    • Rodgau, Hessen, Germany, 63110
      • GSK Investigational Site
    • Wiesbaden, Hessen, Germany, 65205
      • GSK Investigational Site
  • Mecklenburg-Vorpommern
    • Rostock, Mecklenburg-Vorpommern, Germany, 18059
      • GSK Investigational Site
  • Niedersachsen
    • Salzgitter, Niedersachsen, Germany, 38226
      • GSK Investigational Site
    • Wildeshausen, Niedersachsen, Germany, 27793
      • GSK Investigational Site
  • Nordrhein-Westfalen
    • Bad Oeynhausen, Nordrhein-Westfalen, Germany, 32549
      • GSK Investigational Site
    • Balve, Nordrhein-Westfalen, Germany, 58802
      • GSK Investigational Site
    • Bochum, Nordrhein-Westfalen, Germany, 44791
      • GSK Investigational Site
    • Datteln, Nordrhein-Westfalen, Germany, 45711
      • GSK Investigational Site
    • Detmold, Nordrhein-Westfalen, Germany, 32756
      • GSK Investigational Site
    • Dortmund, Nordrhein-Westfalen, Germany, 44329
      • GSK Investigational Site
    • Dortmund, Nordrhein-Westfalen, Germany, 44379
      • GSK Investigational Site
    • Erkrath, Nordrhein-Westfalen, Germany, 40699
      • GSK Investigational Site
    • Espelkamp, Nordrhein-Westfalen, Germany, 32339
      • GSK Investigational Site
    • Goch, Nordrhein-Westfalen, Germany, 47574
      • GSK Investigational Site
    • Guetersloh, Nordrhein-Westfalen, Germany, 33332
      • GSK Investigational Site
    • Heiligenhaus, Nordrhein-Westfalen, Germany, 42579
      • GSK Investigational Site
    • Hille, Nordrhein-Westfalen, Germany, 32479
      • GSK Investigational Site
    • Kleve-Materborn, Nordrhein-Westfalen, Germany, 47533
      • GSK Investigational Site
    • Krefeld, Nordrhein-Westfalen, Germany, 47798
      • GSK Investigational Site
    • Loehne, Nordrhein-Westfalen, Germany, 32584
      • GSK Investigational Site
    • Minden, Nordrhein-Westfalen, Germany, 32427
      • GSK Investigational Site
    • Moenchengladbach, Nordrhein-Westfalen, Germany, 41061
      • GSK Investigational Site
    • Porta Westfalica, Nordrhein-Westfalen, Germany, 32457
      • GSK Investigational Site
    • Solingen, Nordrhein-Westfalen, Germany, 42719
      • GSK Investigational Site
    • Velbert, Nordrhein-Westfalen, Germany, 42551
      • GSK Investigational Site
    • Viersen, Nordrhein-Westfalen, Germany, 41749
      • GSK Investigational Site
  • Rheinland-Pfalz
    • Frankenthal, Rheinland-Pfalz, Germany, 67227
      • GSK Investigational Site
    • Gau-Odernheim, Rheinland-Pfalz, Germany, 55239
      • GSK Investigational Site
    • Mainz, Rheinland-Pfalz, Germany, 55131
      • GSK Investigational Site
    • Oppenheim, Rheinland-Pfalz, Germany, 55276
      • GSK Investigational Site
    • Speyer, Rheinland-Pfalz, Germany, 67346
      • GSK Investigational Site
    • Trier, Rheinland-Pfalz, Germany, 54290
      • GSK Investigational Site
  • Sachsen
    • Stollberg, Sachsen, Germany, 09366
      • GSK Investigational Site
    • Wurzen, Sachsen, Germany, 04808
      • GSK Investigational Site
  • Schleswig-Holstein
    • Flensburg, Schleswig-Holstein, Germany, 24937
      • GSK Investigational Site
    • Flensburg, Schleswig-Holstein, Germany, 24944
      • GSK Investigational Site
    • Harrislee, Schleswig-Holstein, Germany, 24955
      • GSK Investigational Site
    • Husum, Schleswig-Holstein, Germany, 25813
      • GSK Investigational Site
    • Neumuenster, Schleswig-Holstein, Germany, 24534
      • GSK Investigational Site
    • Niebuell, Schleswig-Holstein, Germany, 25899
      • GSK Investigational Site
  • Thueringen
    • Lobenstein, Thueringen, Germany, 07356
      • GSK Investigational Site
    • Neuhaus am Rennweg, Thueringen, Germany, 98724
      • GSK Investigational Site
    • Weimar, Thueringen, Germany, 99425
      • GSK Investigational Site
• Greece
  • Athens, Greece, 115 27
    • GSK Investigational Site
  • Athens, Greece, 11527
    • GSK Investigational Site
  • Didimoteicho, Greece, 68300
    • GSK Investigational Site
  • Karditsa, Greece, 43100
    • GSK Investigational Site
  • Komotini, Greece, 69 100
    • GSK Investigational Site
  • Thessaloniki, Greece, 54636
    • GSK Investigational Site
  • Veria, Greece, 591 00
    • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 1 year (Child)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
• A male or female between, and including, 12 and 23 months of age at the time of the first vaccination.
• Written informed consent obtained from the parent or guardian of the subject.
• Free of obvious health problems as established by medical history and clinical examination before entering into the study.
• Documented three-dose primary vaccination with DTPa, hepatitis B, inactivated polio and Haemophilus influenzae type b conjugate vaccines, completed at least 180 days before administration of the first study vaccination.

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
• Planned administration/ administration of any vaccine not foreseen by the study protocol, including measles, mumps, rubella, varicella and pneumococcal vaccines, within 30 days before the first dose of vaccine(s) and 30 days after the last dose of vaccine(s).
• Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C, W and/or Y.
• Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroup A, C, W and/or Y.
• Previous booster vaccination against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis or Haemophilus influenzae type b.
• History of meningococcal disease.
• Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination.
• History of reactions or allergic disease likely to be exacerbated by any component of the vaccine(s).
• Major congenital defects or serious chronic illness.
• Acute disease at the time of enrolment.
• Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.

Additional criteria for subjects receiving Infanrix hexa™

• Hypersensitivity reaction due to previous vaccination with Infanrix hexa™.
• Encephalopathy defined as an acute, severe central nervous system disorder occurring within 7 days following vaccination and generally consisting of major alterations in consciousness, unresponsiveness, generalised or focal seizures that persist more than a few hours, with failure to recover within 24 hours.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group A; Meningococcal vaccine GSK134612 co-administered with Infanrix hexa™	Biological: Meningococcal vaccine GSK134612; Single dose intramuscular injection; Biological: Infanrix™ hexa; Single dose intramuscular injection
Experimental: Group B; Meningococcal vaccine GSK134612 followed one month later by Infanrix hexa™	Biological: Meningococcal vaccine GSK134612; Single dose intramuscular injection; Biological: Infanrix™ hexa; Single dose intramuscular injection
Active Comparator: Group C; Infanrix hexa™ followed one month later by Meningococcal vaccine GSK134612	Biological: Meningococcal vaccine GSK134612; Single dose intramuscular injection; Biological: Infanrix™ hexa; Single dose intramuscular injection
Active Comparator: Group D; Meningitec™ vaccination	Biological: Meningitec™; Single dose intramuscular injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers ≥ the Cut-off.	The cut-off for the assay was greater than or equal to (≥) 1:8. The analysis was based only on subjects receiving Nimenrix vaccination at Day 0.	1 month after vaccination with Nimenrix vaccine (Month 1)
Anti-PT, Anti-FHA and Anti-PRN Concentrations	The analysis was based only on subjects receiving Infanrix-hexa vaccination. The results were calculated as geometric mean expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).	1 month after the first vaccination (Month 1)
Number of Subjects With Anti-HBs Concentrations ≥ the Cut-off	The cut-off for the assay was greater than or equal to (≥) 10 milli-interantional units per milliliter (mIU/mL).	1 month after vaccination with Nimenrix vaccine (Month 1)
Number of Subjects With Anti-PRP Concentrations ≥ the Cut-off	The cut-off for the assay was ≥ 1μg/mL.	1 month after vaccination with Nimenrix vaccine (Month 1)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers ≥ the Cut-off Values	The cut-off values for the assay were ≥ 1:8 and ≥ 1:128	At month 0, month 1 and month 2
rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers	The results were tabulated as geometric mean expressed in titers.	At month 0, month 1 and month 2
Number of Subjects With Anti-polysaccharide A (Anti-PSA), Anti-PSC, Anti-PSW, and Anti-PSY ≥ the Cut-off	The cut-off for the assay were ≥ 0.3 microgram per milliliter (μg/mL) and ≥ 2.0 μg/mL, respectively.	At month 0, month 1 and month 2
Anti-polysaccharide A (Anti-PSA), Anti-PSC, Anti-PSW, and Anti-PSY Antibody Concentrations	The results for the assay were tabulated as geometric mean expressed in microgram per milliliter (μg/mL).	At month 0, month 1 and month 2
Number of Seroprotected Subjects for Anti-tetanus Toxoid (Anti-TT)	The cut-off for the assay was ≥ 0.1	At month 0, month 1 and month 2
Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations	The results for the assay were tabulated as geometric mean expressed in internationl units per milliliter (IU/mL).	At month 0, month 1 and month 2
Number of Subjects Seroprotected for Anti-diphtheria (Anti-D) ≥ the Cut-off	The cut-off for the assay was ≥ 0.1	At month 0, month 1 and month 2
Anti-diphtheria (Anti-D) Antibody Concentrations	The results for the assay were tabulated as geometric mean expressed in internationl units per milliliter (IU/mL).	At month 0, month 1 and month 2
Number of Subjects Seroprotected for Anti-polio Type 1, 2 & 3 ≥ the Cut-off	The cut-off for the assay was ≥ 1:8.	At month 0, month 1 and month 2
Anti-polio Type 1, 2 & 3 Titers	The results for the assay were tabulated as geometric mean expressed in titers.	At month 0, 1 and 2
Numbers of Seroprotected Subjects for Anti-PRP ≥ the Cut-off	The cut-off for the assay was ≥ 1.0	At month 0, month 1 and month 2
Anti-PRP Antibody Concentrations	The results for the assay were tabulated as geometric mean expressed in microgram per milliliter (μg/mL).	At month 0, month 1 and month 2
Number of Seroprotected Subjects for Anti-HBs ≥ the Cut-offs	The cut-offs for the assay were ≥ 10 mIU/mL and ≥ 100 mIU/mL respectively .	At month 0, month 1 and month 2
Anti-HBs Antibody Concentrations	The results for the assay were tabulated as geometric mean expressed in milli-international units per milliliter (mIU/mL).	At month 0, month 1 and month 2
Number of Subjects With a Vaccine Response to PT, FHA and PRN Antigens	Vaccine response to these antigens is defined as appearance of antibodies in subjects who were seronegative (antibody concentration < 5 EL.U/mL) at pre-vaccination or as at least a 2-fold increase in post-over pre-vaccination antibody concentrations in subjects seropositive at pre-vaccination. The analysis was based only on subjects receiving experimental vaccination.	1 month after vaccination (Month 1)
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations	The results were tabulated as geometric mean expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).	At month 0, month 1 and month 2
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms Post-meningococcal Vaccination	Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of any local symptom irrespective of intensity grade. Grade 3 Pain was defined as crying when limb was moved/ spontaneously painful.	During the 4-day (Days 0-3) follow-up period after Nimenrix or Meningitec vaccination
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms Post-combined Diphtheria Vaccination	The analysis was based only on subjects receiving combined-diphtheria vaccination.	During the 4-day (Days 0-3) follow-up period after Infanrix-hexa vaccination
Number of Subjects Reporting Any Solicited General Symptoms Following Each Dose	Solicited general symptoms assessed were drowsiness, fever, irritability and loss of appetite. Any was defined as occurrence of any general symptom irrespective of intensity grade and relationship. Subjects in the Nimenrix + Infanrix-hexa Group did not receive a second dose of vaccination.	During the 4-day (Days 0-3) post-vaccination dose 1 (D1) and second dose (D2)
Number of Subjects Reporting Any Rash	Any was defined as occurrence of at least one symptom experienced.	Day 0 - Month 7
Number of Subjects Reporting Any New Onset of Chronic Illnesses (NOCIs)	Any was defined as occurrence of at least one symptom experienced.	Day 0 - Month 7
Number of Subjects Reporting Any Conditions Prompting Emergency Room Visits (ER)	Any was defined as occurrence of at least one symptom experienced.	Day 0 - Month 7
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the First Dose	An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined as an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.	Occurring within Day 0-30 following vaccination
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the Second Dose	An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined as an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination. The analysis was based only on subjects receiving a second dose of vaccination.	Occurring within Day 0-30 following vaccination
Number of Subjects Reporting Any Serious Adverse Events (SAEs)	Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.	From dose 1 (Month 0) up to study end (Month 7)

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, Fischbach T, Zinke H, Pankow-Culot H, Papaevangelou V, Bianco V, Van der Wielen M, Miller JM. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine. 2011 Jun 6;29(25):4264-73. doi: 10.1016/j.vaccine.2011.03.009. Epub 2011 Mar 21.
• Maurer H et al. Co-administration of MENACWY-TT conjugate vaccine with DTPA-HBV-IPV/HIB vaccine does not impair immune response to DTPA-HBV-IPV/HIB, and has an acceptable safety profile. Abstract presented at the 28th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID). Nice, France, 4-8 May 2010.

Helpful Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Study record dates

Study Major Dates

• Study Start: August 1, 2007
• Primary Completion (Actual): May 26, 2008
• Study Completion (Actual): October 27, 2008

Study Registration Dates

• First Submitted: July 26, 2007
• First Submitted That Met QC Criteria: July 26, 2007
• First Posted (Estimate): July 27, 2007

Study Record Updates

• Last Update Posted (Actual): January 24, 2019
• Last Update Submitted That Met QC Criteria: August 7, 2018
• Last Verified: May 1, 2017

More Information

Terms related to this study

• Keywords: Safety; Immunogenicity; Meningococcal vaccine; Routine infancy vaccination
• Additional Relevant MeSH Terms: Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Neisseriaceae Infections; Meningococcal Infections
• Other Study ID Numbers: 109835

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Study Data/Documents

1. Study Protocol
   Information identifier: 109835
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
2. Annotated Case Report Form
   Information identifier: 109835
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
3. Clinical Study Report
   Information identifier: 109835
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
4. Dataset Specification
   Information identifier: 109835
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
5. Individual Participant Data Set
   Information identifier: 109835
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
6. Informed Consent Form
   Information identifier: 109835
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
7. Statistical Analysis Plan
   Information identifier: 109835
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register